MedPath

Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma.

Phase 2
Conditions
Hepatocellular Carcinoma
Registration Number
NCT00043433
Lead Sponsor
Tularik
Brief Summary

The purpose of the study is to determine whether T900607-sodium is effective and safe in treating hepatocellular carcinoma, a type of liver cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
35
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (12)

Scripps Health Center

🇺🇸

La Jolla, California, United States

University of California San Diego

🇺🇸

La Jolla, California, United States

George Washington University

🇺🇸

Washington, District of Columbia, United States

H. Lee Moffitt Cancer Center

🇺🇸

Tampa, Florida, United States

Ellis Fischel Cancer Center

🇺🇸

Columbia, Missouri, United States

University of New Mexico

🇺🇸

Albuquerque, New Mexico, United States

University of Rochester

🇺🇸

Rochester, New York, United States

Ireland Cancer Center

🇺🇸

Cleveland, Ohio, United States

University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Fox Chase Cancer Center

🇺🇸

Philadelphia, Pennsylvania, United States

Scroll for more (2 remaining)
Scripps Health Center
🇺🇸La Jolla, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.